LIXT News and Press, Lixte Biotechnology Holdings Inc. From 03/01/21

Lixte Biotechnology (LIXT) enters agreement for purchase and sale of 1.3M shares of common stock, at a purchase price of $3.70 per share, in a registered direct offering; gross proceeds $4.19M. Closing expected on or about March 2, 2021.Gross proceeds from the offering are expected ...

East Setauket, March 01, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has entered into definitive agre...

Athenex (ATNX) -55% on Q4 earnings release and on FDA rejection of oral paclitaxel application in breast cancer.Xtant Medical Holdings (XTNT) -16%.PLx Pharma (PLXP) -9% after FDA OKs PLx Pharma's Vazalore applications.Lixte Biotechnology Holdings (LIXT) -12%.Amer...

LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS) Syndromes Phase 1b/2 for Advanced Soft Tissue Sarcoma Phase 0 (Pharmacodynamics) for Glioblastoma Multiforme Phase 1b for Small Cell Lu...

Nano-cap Lixte Biotechnology ([[LIXT]] +11.5%) along with City of Hope, an independent biomedical research and treatment center, will start a Phase 1b trial to assess the combination of Lixte’s protein phosphatase inhibitor LB-100 with a standard regimen for untreat...

EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced an agreement on a Phase 1b clinical trial with ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadIt is a very light calendar ahead of the Christmas break with just a few earnings reports and no investor conferences at ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc. JERSEY CITY, N.J. , Dec. 1, 2020 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution...

East Setauket, NY, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) (Nasdaq: Common stock – LIXT; Warrants – LIXTW), a drug discovery company that uses biomarker technology to identify enzyme target...